A Phase 1, Single-Center, Dose-Escalation Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF614 in Healthy Subjects Compared to OxyContin®

Trial Profile

A Phase 1, Single-Center, Dose-Escalation Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF614 in Healthy Subjects Compared to OxyContin®

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Oxycodone (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Acronyms SAD
  • Sponsors Ensysce Biosciences
  • Most Recent Events

    • 02 Dec 2017 Cohort 7 has been added into the study and 16 subjects were enrolled for the cohort.
    • 02 Dec 2017 Planned number of patients changed from 48 to 64.
    • 02 Dec 2017 Planned End Date changed from 1 Jun 2017 to 5 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top